FeesSafety
Pluang+

Bitmine buys $69M more ETH, now holding 5.93M tokens, 4.9% of total supply.

Market News
14 Sep 2026
Crypto Economy
View Source
Bullish
Bitmine buys $69M more ETH, now holding 5.93M tokens, 4.9% of total supply.

Bitmine Immersion Technologies has increased its Ethereum (ETH) holdings by purchasing $69 million worth of tokens. The company now holds 5.93 million ETH, which represents 4.9% of the total circulating supply. This significant accumulation reflects Bitmine's bullish outlook on ETH's future value. The current price per ETH is $2,495 according to Coinbase data, indicating strong confidence in the cryptocurrency's potential growth.

The story about Bitmine Immersion Technologies' Ethereum accumulation is presented with Pluang's market data as context. As of Sep 14, 2026 20:03 WIB, out of 50 major cryptocurrencies tradable on Pluang, 30 rose and 19 fell. Notable price changes include EOS at Rp12.649 with an 8.13% increase, XLM at Rp3.382 up 8.02%, and XRP at Rp24.589 rising 4.18%, with EOS showing the highest 1-day change among them.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
48 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
48 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
48 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App